{"transactions":[{"id":1008012,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-04T21:34:49.000Z","date":"2025-10-27","kind":"grant","planned":false,"acquired":true,"shares":35200,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents stock options granted in connection with the reporting person's appointment to the Issuer's Board of Directors. The stock options were granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, and vest in three equal annual installments, beginning on the first anniversary of the date of the grant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents stock options granted in connection with the reporting person's appointment to the Issuer's Board of Directors. The stock options were granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, and vest in three equal annual installments, beginning on the first anniversary of the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted in connection with the reporting person's appointment to the Issuer's Board of Directors. The stock options were granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, and vest in three equal annual installments, beginning on the first anniversary of the date of the grant."}],"balance_after":35200,"derivative":{"exercise_price":3.9,"expiration_date":"2035-10-27","underlying":"Common Stock","underlying_shares":35200},"source":{"system":"sec-edgar","filing":"0001531178-25-000007","document":"form4-11042025_091145.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000153117825000007/form4-11042025_091145.xml","form_type":"4"}},{"id":1664888,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Appreciation Right","published_at":"2024-01-31T17:04:32.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The award will vest in full on the two-year anniversary of the grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"Upon exercise, the Stock Appreciation Right will be settled in cash."}],"balance_after":500000,"derivative":{"exercise_price":2.46,"expiration_date":"2026-03-03","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001867096-24-000014","document":"wk-form4_1706738662.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000186709624000014/wk-form4_1706738662.xml","form_type":"4"}},{"id":1664887,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-01-31T17:04:32.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":1500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years."}],"balance_after":3788064,"source":{"system":"sec-edgar","filing":"0001867096-24-000014","document":"wk-form4_1706738662.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000186709624000014/wk-form4_1706738662.xml","form_type":"4"}},{"id":1811725,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-08-09T18:57:08.000Z","date":"2023-08-09","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":2.3794,"value":23794.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.365 to $2.3899, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":2288064,"source":{"system":"sec-edgar","filing":"0001867096-23-000117","document":"wk-form4_1691621818.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000186709623000117/wk-form4_1691621818.xml","form_type":"4"}},{"id":2038297,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-02-01T16:13:39.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years."}],"balance_after":2278064,"source":{"system":"sec-edgar","filing":"0001867096-23-000023","document":"wf-form4_167528599539937.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000186709623000023/wf-form4_167528599539937.xml","form_type":"4"}},{"id":2086177,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-12-14T16:11:11.000Z","date":"2022-12-13","kind":"purchase","acquired":true,"shares":20000,"price":1.45,"value":29000.0,"ownership":{"direct":true},"balance_after":1528064,"source":{"system":"sec-edgar","filing":"0001867096-22-000131","document":"wf-form4_167105224000343.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000186709622000131/wf-form4_167105224000343.xml","form_type":"4"}},{"id":2271625,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-05-13T16:19:41.000Z","date":"2022-05-12","kind":"purchase","acquired":true,"shares":100000,"price":1.4038,"value":140380.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $1.28 to $1.51, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":1508064,"source":{"system":"sec-edgar","filing":"0001867096-22-000067","document":"wf-form4_165247311184773.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000186709622000067/wf-form4_165247311184773.xml","form_type":"4"}},{"id":2442928,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-01-05T18:16:06.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years."}],"balance_after":1408064,"source":{"system":"sec-edgar","filing":"0001867096-22-000007","document":"wf-form4_164142455326024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000186709622000007/wf-form4_164142455326024.xml","form_type":"4"}},{"id":2510034,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-11-16T16:25:02.000Z","date":"2021-11-15","kind":"purchase","acquired":true,"shares":20000,"price":2.2832,"value":45664.0,"ownership":{"direct":false,"nature":"By: Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.275 to $2.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":33430,"source":{"system":"sec-edgar","filing":"0001867096-21-000080","document":"wf-form4_163709769269955.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000186709621000080/wf-form4_163709769269955.xml","form_type":"4"}},{"id":2514450,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-11-12T17:09:23.000Z","date":"2021-11-11","kind":"purchase","acquired":true,"shares":200000,"price":2.0788,"value":415760.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.97 to $2.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":808064,"source":{"system":"sec-edgar","filing":"0001867096-21-000076","document":"wf-form4_163675494375366.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000186709621000076/wf-form4_163675494375366.xml","form_type":"4"}},{"id":2548095,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T19:49:44.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."}],"balance_after":400000,"derivative":{"exercise_price":5.08,"expiration_date":"2031-01-31","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000899243-21-039335","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000089924321039335/doc4.xml","form_type":"4"}},{"id":2548094,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T19:49:44.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."}],"balance_after":200000,"derivative":{"exercise_price":13.88,"expiration_date":"2029-01-31","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-21-039335","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000089924321039335/doc4.xml","form_type":"4"}},{"id":2548093,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T19:49:44.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":98252,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"These options are early exercisable."}],"balance_after":98252,"derivative":{"exercise_price":5.93,"expiration_date":"2028-01-31","underlying":"Common Stock","underlying_shares":98252},"source":{"system":"sec-edgar","filing":"0000899243-21-039335","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000089924321039335/doc4.xml","form_type":"4"}},{"id":2548092,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T19:49:44.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":69822,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These options are fully vested as of the date hereof."}],"balance_after":69822,"derivative":{"exercise_price":1.55,"expiration_date":"2027-06-11","underlying":"Common Stock","underlying_shares":69822},"source":{"system":"sec-edgar","filing":"0000899243-21-039335","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000089924321039335/doc4.xml","form_type":"4"}},{"id":2548091,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T19:49:44.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":668065,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These options are fully vested as of the date hereof."}],"balance_after":668065,"derivative":{"exercise_price":1.55,"expiration_date":"2027-01-27","underlying":"Common Stock","underlying_shares":668065},"source":{"system":"sec-edgar","filing":"0000899243-21-039335","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000089924321039335/doc4.xml","form_type":"4"}},{"id":2548090,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-05T19:49:44.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":13430,"ownership":{"direct":false,"nature":"By Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Merger Effective Time\"), all existing shares of Xeris common stock (the \"Xeris common stock\") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective time, net of shares withheld for tax."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Merger Effective Time\"), all existing shares of Xeris common stock (the \"Xeris common stock\") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective time, net of shares withheld for tax."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":13430,"source":{"system":"sec-edgar","filing":"0000899243-21-039335","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000089924321039335/doc4.xml","form_type":"4"}},{"id":2548089,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-05T19:49:44.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":410833,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the \"HoldCo RSU\"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the \"Xeris RSU\") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the \"HoldCo RSU\"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the \"Xeris RSU\") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the \"HoldCo RSU\"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the \"Xeris RSU\") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU."}],"balance_after":608064,"source":{"system":"sec-edgar","filing":"0000899243-21-039335","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000089924321039335/doc4.xml","form_type":"4"}},{"id":2548088,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-05T19:49:44.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":197231,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Merger Effective Time\"), all existing shares of Xeris common stock (the \"Xeris common stock\") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective time, net of shares withheld for tax."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Merger Effective Time\"), all existing shares of Xeris common stock (the \"Xeris common stock\") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective time, net of shares withheld for tax."}],"balance_after":197231,"source":{"system":"sec-edgar","filing":"0000899243-21-039335","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000089924321039335/doc4.xml","form_type":"4"}},{"id":2548339,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T17:36:51.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."}],"balance_after":0,"derivative":{"exercise_price":5.08,"expiration_date":"2031-01-31","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000899243-21-039254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039254/doc4.xml","form_type":"4"}},{"id":2548338,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T17:36:51.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."}],"balance_after":0,"derivative":{"exercise_price":13.88,"expiration_date":"2029-01-31","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-21-039254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039254/doc4.xml","form_type":"4"}},{"id":2548337,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T17:36:51.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":98252,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"These options are early exercisable."}],"balance_after":0,"derivative":{"exercise_price":5.93,"expiration_date":"2028-01-31","underlying":"Common Stock","underlying_shares":98252},"source":{"system":"sec-edgar","filing":"0000899243-21-039254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039254/doc4.xml","form_type":"4"}},{"id":2548336,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T17:36:51.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":69822,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These options are fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":1.55,"expiration_date":"2027-06-11","underlying":"Common Stock","underlying_shares":69822},"source":{"system":"sec-edgar","filing":"0000899243-21-039254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039254/doc4.xml","form_type":"4"}},{"id":2548335,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T17:36:51.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":668065,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These options are fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":1.55,"expiration_date":"2027-01-27","underlying":"Common Stock","underlying_shares":668065},"source":{"system":"sec-edgar","filing":"0000899243-21-039254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039254/doc4.xml","form_type":"4"}},{"id":2548334,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-10-05T17:36:51.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":13430,"ownership":{"direct":false,"nature":"By Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), all existing shares of Xeris common stock (the \"Xeris common stock\") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax."},{"field":"shares","element":"transactionShares","label":"F4","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), all existing shares of Xeris common stock (the \"Xeris common stock\") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-039254","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039254/doc4.xml","form_type":"4"}},{"id":2548333,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-10-05T17:36:51.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":410833,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the \"Xeris RSU\"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the \"HoldCo RSU\") on the same terms and conditions  (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the \"Xeris RSU\"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the \"HoldCo RSU\") on the same terms and conditions  (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the \"Xeris RSU\"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the \"HoldCo RSU\") on the same terms and conditions  (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-039254","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039254/doc4.xml","form_type":"4"}},{"id":2548332,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-10-05T17:36:51.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":197231,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), all existing shares of Xeris common stock (the \"Xeris common stock\") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), all existing shares of Xeris common stock (the \"Xeris common stock\") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax."}],"balance_after":410833,"source":{"system":"sec-edgar","filing":"0000899243-21-039254","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039254/doc4.xml","form_type":"4"}},{"id":2888347,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-01T16:22:57.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of these shares shall vest on January 29, 2022, with the remainder vesting ratably over the following 36 months."}],"balance_after":400000,"derivative":{"exercise_price":5.08,"expiration_date":"2031-01-29","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001346302-21-000016","document":"wf-form4_161221455011261.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000134630221000016/wf-form4_161221455011261.xml","form_type":"4"}},{"id":2888346,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-02-01T16:22:57.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These restricted stock units vest in three substantially equal annual installments beginning on January 29, 2022."}],"balance_after":636134,"source":{"system":"sec-edgar","filing":"0001346302-21-000016","document":"wf-form4_161221455011261.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000134630221000016/wf-form4_161221455011261.xml","form_type":"4"}},{"id":2949865,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-12-10T16:52:44.000Z","date":"2020-12-09","kind":"purchase","acquired":true,"shares":10000,"price":4.0551,"value":40551.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.04 to $4.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":411134,"source":{"system":"sec-edgar","filing":"0001346302-20-000075","document":"wf-form4_160763715074716.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000134630220000075/wf-form4_160763715074716.xml","form_type":"4"}},{"id":3118194,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-08T23:00:47.000Z","date":"2020-06-05","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments over the 12 months commencing July 5, 2020, provided that the shares subject to this option shall vest in full on the date of Issuer's 2021 annual meeting of shareholders, subject to recipient continuing to provide service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":3.74,"expiration_date":"2030-06-05","underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-035111","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000120919120035111/doc4.xml","form_type":"4"}},{"id":3154099,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-05-11T17:06:05.000Z","date":"2020-05-08","kind":"purchase","acquired":true,"shares":33000,"price":3,"value":99000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.72 to $3.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":401134,"source":{"system":"sec-edgar","filing":"0000899243-20-012590","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924320012590/doc4.xml","form_type":"4"}},{"id":3237518,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-03-02T16:52:34.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":185000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These restricted stock units vest in three substantially equal annual installments beginning on January 31, 2021."}],"balance_after":368134,"source":{"system":"sec-edgar","filing":"0000899243-20-006512","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924320006512/doc4.xml","form_type":"4"}},{"id":3266269,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-02-18T17:02:19.000Z","date":"2020-02-14","kind":"purchase","acquired":true,"shares":20000,"price":4.15,"value":83000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares purchased in an underwritten public offering of the Issuer at the public offering price of $4.15 per share."}],"balance_after":183134,"source":{"system":"sec-edgar","filing":"0000899243-20-004912","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924320004912/doc4.xml","form_type":"4"}},{"id":3290824,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-02-04T17:00:55.000Z","date":"2020-01-31","kind":"tax_withholding","acquired":false,"shares":9801,"price":6.37,"value":62432.37,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on January 31, 2020. No shares were sold in connection with this transaction."}],"balance_after":163134,"source":{"system":"sec-edgar","filing":"0000899243-20-002835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924320002835/doc4.xml","form_type":"4"}},{"id":3357136,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2019-11-27T16:43:32.000Z","date":"2019-11-25","kind":"purchase","acquired":true,"shares":17935,"price":8.5466,"value":153283.271,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.48 to $8.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":172935,"source":{"system":"sec-edgar","filing":"0000899243-19-028235","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924319028235/doc4.xml","form_type":"4"}},{"id":3508416,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-05-29T16:24:56.000Z","date":"2019-05-24","kind":"exercise","acquired":false,"shares":6154,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units converted into ordinary shares on a one-for-one basis upon vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On May 24, 2018, the reporting person was granted an award of 6,154 restricted stock units, which vested on May 24, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On May 24, 2018, the reporting person was granted an award of 6,154 restricted stock units, which vested on May 24, 2019."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":6154},"source":{"system":"sec-edgar","filing":"0000899243-19-015017","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000089924319015017/doc4.xml","form_type":"4"}},{"id":3508415,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-29T16:24:56.000Z","date":"2019-05-24","kind":"exercise","acquired":true,"shares":6154,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units converted into ordinary shares on a one-for-one basis upon vesting of the units."}],"balance_after":31390,"source":{"system":"sec-edgar","filing":"0000899243-19-015017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000089924319015017/doc4.xml","form_type":"4"}},{"id":3598994,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2019-03-12T19:15:03.000Z","date":"2019-03-11","kind":"purchase","acquired":true,"shares":30000,"price":9.1195,"value":273585.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.98 to $9.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":155000,"source":{"system":"sec-edgar","filing":"0000899243-19-007350","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924319007350/doc4.xml","form_type":"4"}},{"id":3679410,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-01T16:42:43.000Z","date":"2019-01-31","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."}],"balance_after":200000,"derivative":{"exercise_price":13.88,"expiration_date":"2029-01-31","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-19-002330","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924319002330/doc4.xml","form_type":"4"}},{"id":3679409,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2019-02-01T16:42:43.000Z","date":"2019-01-31","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. 25% of these restricted stock units shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."}],"balance_after":125000,"source":{"system":"sec-edgar","filing":"0000899243-19-002330","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924319002330/doc4.xml","form_type":"4"}},{"id":3832476,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-08-27T17:15:26.000Z","date":"2018-08-23","kind":"purchase","acquired":true,"shares":500,"price":10.4374,"value":5218.7,"ownership":{"direct":true},"balance_after":25236,"source":{"system":"sec-edgar","filing":"0001209191-18-048518","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000120919118048518/doc4.xml","form_type":"4"}},{"id":3882088,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Series C Preferred Stock","published_at":"2018-06-27T20:38:46.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":23922,"ownership":{"direct":false,"nature":"By Paul R. Edick 2008 Revocable Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13430},"source":{"system":"sec-edgar","filing":"0000899243-18-018506","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924318018506/doc4.xml","form_type":"4"}},{"id":3882087,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-06-27T20:38:46.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":13430,"ownership":{"direct":false,"nature":"By Paul R. Edick 2008 Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date."}],"balance_after":13430,"source":{"system":"sec-edgar","filing":"0000899243-18-018506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924318018506/doc4.xml","form_type":"4"}},{"id":3897539,"issuer":{"id":143144,"kind":"organization","name":"PDL BIOPHARMA, INC.","symbol":"PDLI"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2018-06-12T20:29:50.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":54348,"price":2.76,"value":150000.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The grant will cliff-vest on the first anniversary of the date of grant so long as the grant recipient continues to serve on the Board of Directors of PDL BioPharma, Inc."}],"balance_after":214563,"source":{"system":"sec-edgar","filing":"0000882104-18-000067","document":"wf-form4_152883537177125.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882104/000088210418000067/wf-form4_152883537177125.xml","form_type":"4"}},{"id":3913738,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-2 Preferred Shares","published_at":"2018-05-30T17:22:29.000Z","date":"2018-05-30","kind":"exercise","acquired":false,"shares":1591,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1591},"source":{"system":"sec-edgar","filing":"0001209191-18-034201","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000120919118034201/doc4.xml","form_type":"4"}},{"id":3913737,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-1 Preferred Shares","published_at":"2018-05-30T17:22:29.000Z","date":"2018-05-30","kind":"exercise","acquired":false,"shares":4050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":4050},"source":{"system":"sec-edgar","filing":"0001209191-18-034201","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000120919118034201/doc4.xml","form_type":"4"}},{"id":3913736,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Shares","published_at":"2018-05-30T17:22:29.000Z","date":"2018-05-30","kind":"exercise","acquired":false,"shares":15913,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":15913},"source":{"system":"sec-edgar","filing":"0001209191-18-034201","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000120919118034201/doc4.xml","form_type":"4"}},{"id":3913735,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-30T17:22:29.000Z","date":"2018-05-30","kind":"exercise","acquired":true,"shares":1591,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."}],"balance_after":24736,"source":{"system":"sec-edgar","filing":"0001209191-18-034201","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000120919118034201/doc4.xml","form_type":"4"}},{"id":3913734,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-30T17:22:29.000Z","date":"2018-05-30","kind":"exercise","acquired":true,"shares":4050,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."}],"balance_after":23145,"source":{"system":"sec-edgar","filing":"0001209191-18-034201","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000120919118034201/doc4.xml","form_type":"4"}},{"id":3913733,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-30T17:22:29.000Z","date":"2018-05-30","kind":"exercise","acquired":true,"shares":15913,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."}],"balance_after":19095,"source":{"system":"sec-edgar","filing":"0001209191-18-034201","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000120919118034201/doc4.xml","form_type":"4"}},{"id":3915074,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-05-29T17:26:23.000Z","date":"2018-05-24","kind":"grant","acquired":true,"shares":6154,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Ordinary Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person providing continuous service, the RSU shall vest on May 24, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person providing continuous service, the RSU shall vest on May 24, 2019."}],"balance_after":6154,"derivative":{"underlying":"Ordinary Shares","underlying_shares":6154},"source":{"system":"sec-edgar","filing":"0001209191-18-033908","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1531178/000120919118033908/doc4.xml","form_type":"4"}},{"id":4062251,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2018-02-13T16:54:53.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":10000,"price":7.7,"value":77000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the \"Option Spread\"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":10.3,"expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001171843-18-001108","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184318001108/form4.xml","form_type":"4"}},{"id":4062250,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, Class A","published_at":"2018-02-13T16:54:53.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":14930,"price":18,"value":268740.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the \"Merger Agreement\"). The common stock consisted of restricted stock units that were accelerated as a result of the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001171843-18-001108","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184318001108/form4.xml","form_type":"4"}},{"id":4260733,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2017-07-07T16:55:18.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vesting commences July 1, 2017 in 12-monthly installments."}],"balance_after":10000,"derivative":{"exercise_price":10.3,"expiration_date":"2027-06-01","underlying":"Class A Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001171843-17-004005","document":"formfoura.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184317004005/formfoura.xml","form_type":"4/A","original_submission_date":"2017-06-05"}},{"id":4260732,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-07-07T16:55:18.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":5130,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Common stock granted consists of restricted stock units that vest in a single installment on June 1, 2018."}],"balance_after":19830,"source":{"system":"sec-edgar","filing":"0001171843-17-004005","document":"formfoura.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184317004005/formfoura.xml","form_type":"4/A","original_submission_date":"2017-06-05"}},{"id":4264254,"issuer":{"id":141061,"kind":"organization","name":"Neos Therapeutics, Inc.","symbol":"NEOS"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-07-05T17:59:26.000Z","date":"2017-07-03","kind":"grant","acquired":true,"shares":18322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests in equal quarterly installments over a one-year period which begins on June 15, 2017."}],"balance_after":18322,"derivative":{"exercise_price":7.65,"expiration_date":"2027-07-03","underlying":"Common Stock","underlying_shares":18322},"source":{"system":"sec-edgar","filing":"0001104659-17-043628","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1467652/000110465917043628/a4.xml","form_type":"4"}},{"id":4286288,"issuer":{"id":143144,"kind":"organization","name":"PDL BIOPHARMA, INC.","symbol":"PDLI"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2017-06-13T00:19:43.000Z","date":"2017-06-09","kind":"grant","acquired":true,"shares":60729,"price":2.47,"value":150000.63,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The grant will cliff-vest on the first anniversary of the date of grant so long as the grant recipient continues to serve on the Board of Directors of PDL BioPharma, Inc. During the one-year vesting period, the grant recipient will have the right to vote the shares and receive any dividends and other distributions paid, except that dividends and other distributions will be accumulated and will vest and be paid, with interest, on the earlier of the same vesting conditions as the original award or March 15th of the year following the payment of such dividend or distribution to all stockholders."}],"balance_after":160215,"source":{"system":"sec-edgar","filing":"0000882104-17-000065","document":"wf-form4_149731316693886.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882104/000088210417000065/wf-form4_149731316693886.xml","form_type":"4"}},{"id":4292386,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2017-06-05T21:59:47.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vesting commences July 1, 2017 in 12-monthly installments."}],"balance_after":10000,"derivative":{"exercise_price":10.3,"expiration_date":"2027-06-01","underlying":"Class A Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001171843-17-003483","document":"f4_edick060517.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184317003483/f4_edick060517.xml","form_type":"4"}},{"id":4292385,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-05T21:59:47.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":5130,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Common stock granted consists of restricted stock units that vest in a single installment on June 1, 2018."}],"balance_after":14930,"source":{"system":"sec-edgar","filing":"0001171843-17-003483","document":"f4_edick060517.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184317003483/f4_edick060517.xml","form_type":"4"}},{"id":4318645,"issuer":{"id":85102,"kind":"organization","name":"LUMOS PHARMA, INC.","symbol":"(LUMO)"},"owners":[{"id":73624,"kind":"person","name":"Edick Paul R","position":1,"cik":"0001531178","reported_name":"Edick Paul R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-16T17:20:35.000Z","date":"2017-05-12","kind":"grant","acquired":true,"shares":13309,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Automatic grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan (the \"Plan\").  One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date.  The option expires ten years after the date of grant."}],"balance_after":13309,"derivative":{"exercise_price":17.42,"expiration_date":"2027-05-11","underlying":"Common Stock","underlying_shares":13309},"source":{"system":"sec-edgar","filing":"0001126234-17-000052","document":"wf-form4_149496962117427.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1126234/000112623417000052/wf-form4_149496962117427.xml","form_type":"4"}}]}